Skip to content

EBITDA at other companies

Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
-$53.58M-17.9%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$60.37M-93.8%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
-$124.73M-2.3%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$83.01M+14.0%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
-$102.98M-38.6%
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Revenue-
Operating income-$102.0M-32.3%
Net income-$105.5M-41.2%
EPS (diluted)-$0.83-23.9%

Balance sheet

See full
Cash & equivalents$430.5M+212%
Total debt$205.7M+226%
Total equity$276.0M-11.6%
Total assets$535.3M+31.3%

Cash flow

See full
Operating cash flow-$82.1M-4.4%
CapEx$68.0K-74.9%
Free cash flow-$82.2M-4.1%

Valuation

See full
Market cap$5.67B+85.5%

Profitability

See full
Operating margin-231.8%
Net margin-236.9%
FCF margin-309.1%

Returns & leverage

See full
Return on equity-138.9%+60.1pp
Debt / equity0.7×+0.5×
Current ratio8.6×-1.6×

Where this comes from

Calculated from Scholar Rock’s reported figures.

$102.0Mebit+
$335.0KDepreciation Depletion & Amortization
=-$101.68M

The official record: Scholar Rock’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Scholar Rock's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Scholar Rock's EBITDA?
Scholar Rock (SRRK) reported EBITDA of -$101.68M in Q1 2026.
How has Scholar Rock's EBITDA changed year-over-year?
Scholar Rock's EBITDA decreased by 32.6% year-over-year, from -$76.7M to -$101.68M.
What is the long-term trend for Scholar Rock's EBITDA?
Over 4 years (2021 to 2025), Scholar Rock's EBITDA has grown at a 31.7% compound annual growth rate (CAGR), from -$127.29M to -$382.99M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.